Indoleamine 2,3-Dioxygenase Inhibitory Activity of Derivatives of Marine Alkaloid Tsitsikammamine A Dr. Eduard Dolušić Drug Design and Discovery Center.

Slides:

Advertisements

Similar presentations

Structural Bioinformatics in Drug Discovery

Advertisements

Challenges in new drug discovery in South Asia

1 Marine Technology Summit November 16, Discovering and Developing New Medicines from Marine Microbes Nereus Pharmaceuticals Ken Lloyd, Ph.D. Chief.

Modulation of the Cellular Phenotype in Human Colon Adenocarcinoma Cells by Folic Acid and Polyamine Pools Nathan W. Sweeney, Julie A. Buckmeier, Christina.

Effects of Etoposide on the Apoptosis of HL-60 Cells Stefanos F. Haddad a, Glaucia V. Faheina-Martins b,c, Demetrius A. M. Araújo b,c a Department of Biology,

Pd(II)-Catalysed Cyclisations of Aminoalkenitols Dr. Peter Szolcsányi Department of Organic Chemistry Slovak University of Technology Bratislava, Slovak.

Department of Chemistry Seminar Announcement Date/Time/VenueTitle/Speaker 21 Feb (Mon) 4pm – S8 Level 3 Executive Classroom Natural products and.

AROMATIC THIOSEMICARBAZONES ARE INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO), AN EMERGING TARGET FOR CANCER TREATMENT Introduction and aim of the work.

1) (a) Jin, Zh. Nat. Prod. Rep. 2006, 23, 464; (b) Turner, G. L. et al, Angew. Chem. Int. Ed. 2007, 46, 7996; (c) Bagley, M. C. et al, Chem. Rev. 2005,

Synthesis of Lamellarin D A Novel Potent Inhibitor of DNA Topoisomerase I Wenhui Hao March 16 th, 2006.

Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3- dioxygenase (IDO), a promising target for anti-cancer immunotherapy Eduard Dolušić,

Dionicio Siegel – Accessing, Understanding, and Optimizing Compounds We are interested in: Providing synthetic access to unique compounds with promising.

Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,

Kyoto University, Japan

Amino Acids (20 different ones) Proteins = long chains of amino acids Structure: collagen, keratin Enzymes: perform reactions Receptors: signal changes.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

1 BE : An Inhibitor of DNA –Topoisomerase II Indira Thapa November 24, 2005.

Novel Inhibitors of Indoleamine 2,3-Dioxygenase (IDO), a Target for Anti-Cancer Immunotherapy Introduction. Immunotherapy is a promising novel strategy.

Bill Gerwick, OSU. What are Secondary Metabolites? Also known as natural products, secondary metabolites are organic compounds (small molecules) that.

Optimization of Partial Hydrogenation Parameters Envisaged Flow Synthesis of 1 Z-Selective semi-hydrogenation of alkynes under continuous flow as part.

Bill Gerwick Research Interests Characterizing the ‘weird and wonderful’ natural products of marine algae and cyanobacteria Drug discovery from marine.

This work is supported by the FNRS and the Walloon Region (BioWin project CANTOL: Convention n° 5678). 4. References 1. Introduction 2. Synthesis and its.

© Copyright 2015 Galapagos NV Poster available online at: Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three.

Macitentan – A novel sulfamide

Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.

Differential activity of synthetic Au (III) and Pt (II) diethyldithiocarbamate complexes towards the proteasome in hepatoma cell line SK-Hep1 INTRODUCTION.

Synthesis of Leucascandrolide A via a Spontaneous Macrolactolization J. Am. Chem. Soc. 2002, 124, Presented by Vijayarajan Devannah 3/19/2013.

Towards an Integrated Research Policy in the Area of Drug Discovery in the Arab Countries Including mechanisms to better utilization of their terrestrial.

Activity Enhancement of the Synthetic Syrbactin Proteasome Inhibitor Hybrid and Biological Evaluation in Tumor Cells Crystal R. Archer, Michael Groll,

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase 1 (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoural.

Today’s Drug Discovery Process “How Do We Discover Drugs” Dr. Vincent P. Gullo Drew University.

RISE Honors Seminar 2014 Ronald Doll RISE Dept. S-332 X 3168 Training – Synthetic Organic Chemist (Ph.D. Duke Univ.) - National Institute.

26th April 2016, BioTrinity - London

1 Gary Gellerman Department of Chemical Sciences Ariel University Israel 8th International Conference on Pharmaceuticals and Novel DD Systems.

ISMN- CNR Palermo a Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), Consiglio Nazionale delle Ricerche (CNR), Via U. La Malfa 153, Palermo,

Small Molecule Inhibitors of Phagocytosis for Treatment of Immune Cytopenias D. R. Branch 1, 2, M. K. Purohit 3, I. Scovell 2, A. Neschadim 2, Y. Katsman.

Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.

Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.

Structural Bioinformatics in Drug Discovery Melissa Passino.

Professor Stephen Pyne School of Chemistry, University of Wollongong, New South Wales 2522, Australia  Research within the Pyne group.

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

Biological activity of novel synthetic tylophorine analogs in MCF-7 breast cancer cells Przemysław Czajkowski 1, Edyta Andrulewicz 1, Anna Bielawska.

PHYTOCHEMICAL INVESTIGATION RESULTS AND DISCUSSION

Sandun Perera, David Piwnica-Worms, and Mian M. Alauddin

Bernard Masereela, Benoît Van den Eyndec and Raphaël Frédéricka

Activity of Carbonic Anhydrase Inhibitors in Breast Cancer Models

Can Drug Discovery Research be Done At An Undergraduate Institution?

Developing chemically modified, non-anticoagulant heparin derivatives as galectin-3-targeted novel anti-cancer/anti-metastasis drugs Professor Lu-Gang.

Inhibitors of type three secretion system [TTSS] protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS Mailing.

Tryptophan 2,3-dioxygenase (TDO) inhibitors : Identification

EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND

Results and Discussion Strategy of Drug Design

FLOW SYNTHESIS OF COMBRETASTATIN A-4

Structural Bioinformatics in Drug Discovery

Discussion Outline Cells of the Immune System.

Figure 2 Multiscale modelling in oncology

Envisaged Flow Synthesis of (1)

Figure 4 Macrophage-targeting antitumour treatment approaches

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

ENVISAGED CONTINUOUS FLOW SYNTHESIS OF COMBRETASTATIN A-4

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Design & Synthesis of Mycobacterium tuberculosis TMPK Inhibitors

Nat. Rev. Nephrol. doi: /nrneph

2. Chemistry Department, Faculty of Science, Cairo University.

Envisaged Flow Synthesis of 1

3. Docking, physicochemistry and in vivo properties

Illustration of cancer cells and tumor microenvironment–deregulated miRNA target networks leading to tumor growth and progression. Illustration of cancer.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Presentation transcript:

Indoleamine 2,3-Dioxygenase Inhibitory Activity of Derivatives of Marine Alkaloid Tsitsikammamine A Dr. Eduard Dolušić Drug Design and Discovery Center Department of Pharmacy University of Namur (FUNDP), Belgium

Indoleamine 2,3-Dioxygenase (IDO) Dr. Eduard Dolušić JFB 2011 Liège 2 R. Schwarcz, Curr. Opin. Pharmacol. 2004, 4, 12.  monomeric (~45 kDa)  protoheme IX prosthetic group  extrahepatic  other substrates: serotonin, melatonin, tryptamine…

Interest in IDO as a drug target Dr. Eduard Dolušić JFB 2011 Liège 3  many human tumors constitutively express IDO Uyttenhove, C. et al, Nat Med 2003, 9,  IDO expression in placenta is required for immune tolerance of fetus by the mother Munn, D. H. et al, Science 1998, 281, Katz, J. B. et al, Imm. Rev. 2008, 222, 206.  cancer immunotherapy shows limited efficacy in vivo; IDO plays a crucial role Munn, D. H.; Mellor, A. L. J. Clin. Invest. 2007, 117, Prendergast, G. C. Oncogene 2008, 27, 3889.

Sugimoto, H. et al, PNAS 2006, 103, Dr. Eduard Dolušić JFB 2011 Liège 4 IDO inhibitors - background  inhibitors (lit.): IC 50 =  M Kumar et al, JMC 2008, 51, K i = 61–70 nM Kumar et al, JMC 2008,51, K i = 200 nM Carr et al, JMC 2008,51, IC 50 =59–86 nM Yue et al, JMC 2009,52, IC 50 = 50  M Röhrig et al, JMC 2010, 53, IC 50 ~100  M clinical trials

Dr. Eduard Dolušić JFB 2011 Liège 5 IDO inhibitors discovered by virtual screening Dolušić, E. et al; Bioorg. Med. Chem. 2011, 19, Dolušić, E. et al; EJMC 2011, doi: /j.ejmech

Dr. Eduard Dolušić JFB 2011 Liège 6 Dolušić, E. et al; Bioorg. Med. Chem. 2011, 19, Dolušić, E. et al; EJMC 2011, doi: /j.ejmech Work on another (HTS) series in progress. IDO inhibitors discovered by virtual screening

Dr. Eduard Dolušić JFB 2011 Liège 7 Marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines Legentil, L. et al; JMC 2006, 49, Delfourne, E.; Anti Canc. Agents Med. Chem. 2008, 8, 910.  wakayin (1): isolated in 1991 from the ascidian Clavelina species  reported to have diverse bioactivities including cytotoxicity and topoisomerase I inhibition  tsitsikammamines A (2) and B (3): isolated in 1996 from a Latrunculiidae sponge  similar bioactivity profile to wakayin  pyrazolic derivatives of general (a) and (b) structures also exhibit topoisomerase I/II inhibitory activity; some of them are cytotoxic

Dr. Eduard Dolušić JFB 2011 Liège : two novel regioisomeric series of tsitsikammamine A analogues - synthesis Rives, A. et al; Eur. J. Med. Chem. 2010, 45, 343.  synthesized on the basis of the Michael addition chemistry a)abs. EtOH, rt, 2h; b) TFA, CH 2 Cl 2, rt, 4h; c) MnO 2, CH 2 Cl 2, rt, overnight; d) abs. EtOH, 4Å MS, , 3h a)1M NaOH, dioxane, rt, overnight; b) BBr 3, CH 2 Cl 2, N 2, 4h

Dr. Eduard Dolušić JFB 2011 Liège 9 Rives, A. et al; Eur. J. Med. Chem. 2010, 45, : two novel regioisomeric series of tsitsikammamine A analogues - synthesis a)abs. EtOH, rt, 2h; b) TFA, CH 2 Cl 2, rt, 4h; c) MnO 2, CH 2 Cl 2, rt, overnight; d) 1M NaOH, dioxane, rt, overnight; e) BBr 3, CH 2 Cl 2, N 2, 4h

Dr. Eduard Dolušić JFB 2011 Liège 10 Rives, A. et al; Eur. J. Med. Chem. 2010, 45, 343.  products were evaluated in an MTT colorimetric antiproliferative assay against several cancer and normal (fibroblast) cell lines  a cytotoxic synthetic intermediate 8b with an unknown mechanism of action was identified 2010: two novel regioisomeric series of tsitsikammamine A analogues – pharmacological evaluation

Dr. Eduard Dolušić JFB 2011 Liège 11 IDO inhibitory activity of tsitsikammamine derivatives

 several tsitsikammamine A analogues display (sub)micromolar potencies in an IDO enzymatic test Conclusion  a number of derivatives are also reasonably active in an IDO cellular test without being toxic  this class of compounds is a potential source of leads for the development of new anticancer compounds with a novel pharmacological profile (manuscript in preparation) Dr. Eduard Dolušić JFB 2011 Liège 12

Dr. Eduard Dolušić JFB 2011 Liège 13 D 3 C, FUNDP Namur Eduard Dolušić Raphaël Frédérick Bernard Masereel Sara Modaffari Laurence Moineaux Christelle Vancraeynest Johan Wouters Ludwig Institute for Cancer Research Brussels Branch Didier Colau Pierre Larrieu Luc Pilotte Vincent Stroobant Benoît Van den Eynde Euroscreen SA Sébastien Blanc Delphine Colette Graeme Fraser Université Paul Sabatier Laboratoire SPMIB Toulouse, France Evelyne Delfourne Arnaud Rives ULB Brussels Lab. de Toxicologie Robert Kiss Benjamin Le Calvé Collaborators €€€ FNRS (Belgium) Biowin (CANTOL: convention n5678) Thank you for your attention!